Signal transduction pathways linking the activation of alveolar macrophages with the recruitment of neutrophils to lungs in chronic obstructive pulmonary disease

Experimental Lung Research

Volumn 35, Issue 6, 2009, Pages 439-485

  Murugan, Vidyasaral ^a   Peck, Michael J ^b  

^a JUBILANT BIOSYS LTD   (India)

^b PHILIP MORRIS PRODUCTS S A   (Switzerland)

Author keywords

Cigarette smoke; COPD; Macrophage; Signaling pathways

Indexed keywords

CELL PROTEIN; CHEMOATTRACTANT; CHEMOTACTIC FACTOR; CIGARETTE SMOKE; GROWTH RELATED ONCOGENE ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 8; LEUKOTRIENE B4; MACROPHAGE CHEMOTACTIC PROTEIN 1; OZONE; TRANSCRIPTION FACTOR AP 1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

CHRONIC OBSTRUCTIVE LUNG DISEASE; DENDRITIC CELL; HUMAN; INFLAMMATION; INFLAMMATORY CELL; LUNG ALVEOLUS MACROPHAGE; LUNG FUNCTION; MACROPHAGE; NEUTROPHIL; NEUTROPHIL CHEMOTAXIS; PATHOGENESIS; PATHOPHYSIOLOGY; PNEUMONIA; PRIORITY JOURNAL; PROTEIN SECRETION; PROTEIN SYNTHESIS; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE; WORLD HEALTH ORGANIZATION;

ANIMALS; CHEMOTACTIC FACTORS; HUMANS; INTERLEUKIN-1BETA; INTERLEUKIN-8; LIPOPOLYSACCHARIDES; LUNG; MACROPHAGE ACTIVATION; MACROPHAGES, ALVEOLAR; MODELS, BIOLOGICAL; NEUTROPHILS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK FACTORS; SIGNAL TRANSDUCTION; SMOKING; TUMOR NECROSIS FACTOR-ALPHA;

EID: 70849131955     PISSN: 01902148     EISSN: 15210499     Source Type: Journal    
DOI: 10.1080/01902140902759290     Document Type: Review

References (177)

1. Lopez AD, et al: Global and regional burden of disease and risk factors, 2001: Systematic analysis of population health data. Lancet. 2006;367:1747-1757.
2. Halbert RJ, et al: Global burden of COPD: Systematic review and meta-analysis. Eur Respir J. 2006;28:523-532.
3. Fukuchi Y, et al: COPD in Japan: The Nippon COPD Epidemiology study. Respirology. 2004;9:458-465.
4. http://www.goldcopd.com/Guidelineitem.aspl1=2&l2=1&intId=996
5. David M, et al: Smoking and Tobacco Control. Monograph 8. Changes in Cigarette-Related Disease Risks and Their Implication for Prevention and Control. NIH Publication. 1997; No. 97- 4213: 1-11.
6. Rabe KF, et al: Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD Executive Summary. Am J Respir Crit Care Med. 2007;176:532-555.
7. Retamales I, et al: Amplification of inflammation in emphysema and its association with latent adenoviral infection. Am J Respir Crit Care Med. 2001;164:469-473.
8. Lofdahl JM, et al: Different inflammatory cell pattern and macrophage phenotype in chronic obstructive pulmonary disease patients, smokers and non-smokers. Clin Exp Immunol. 2006;145:428-437.
9. Ofulue AF, et al: Effects of depletion of neutrophils or macrophages on development of cigarette smoke-induced emphysema. Am J Physiol. 1999;277:L97-L105.
10. Barnes PJ, et al: Alveolar macrophages as orchestrators of COPD. COPD. 2004;1:59-70.
11. Domagala-Kulawik J, et al: Expression of macrophage surface markers in induced sputum of patients with chronic obstructive pulmonary disease. J Physiol Pharmacol. 2006;57(Suppl 4):75-84.
12. Di Stefano A, et al: Severity of airflow limitation is associated with severity of airway inflammation in smokers. Am J Respir Crit Care Med. 1998;158:1277-1285.
13. Tetley TD, et al: Macrophages and the pathogenesis of COPD. Chest. 2002;121(5 Suppl):156S- 159S.
14. Barnes PJ:Mediators of chronic obstructive pulmonary disease. Pharmacol Rev. 2004;56:515-548.
15. Pons AR, et al: Phenotypic characterisation of alveolar macrophages and peripheral blood monocytes in COPD. Eur Respir J. 2005;25:647-652.
16. Bardelli C, et al: Expression of functional NK1 receptors in human alveolar macrophages: Superoxide anion production, cytokine release and involvement of NF-kappaB pathway. Br J Pharmacol. 2005;145:385-396.
17. Gunella G, et al:Macrophage-stimulating protein differently affects human alveolarmacrophages from smoker and non-smoker patients: Evaluation of respiratory burst, cytokine release and NFkappaB pathway. Br J Pharmacol. 2006;148:478-489.
18. Marian E, et al: Up-regulated membrane and nuclear leukotriene B4 receptors in COPD. Chest. 2006;129:1523-1530.
19. Hodge S, et al: Smoking alters alveolar macrophage recognition and phagocytic ability: Implications in COPD. Am J Respir Cell Mol Biol. 2007;37:748-755.
20. Heguy A, et al: Gene expression profiling of human alveolar macrophages of phenotypically normal smokers and nonsmokers reveals a previously unrecognized subset of genes modulated by cigarette smoking. J Mol Med. 2006;84:318-328.
21. Higashimoto Y, et al: Effect of chronic tobacco smoke exposure on the function of alveolar macrophages in mice. Respiration. 1994;61:23-27.
22. Kirkham PA, et al: Macrophage phagocytosis of apoptotic neutrophils is compromised by matrix proteins modified by cigarette smoke and lipid peroxidation products. Biochem Biophys Res Commun. 2004;318:32-37.
23. Woodruff PG, et al: A distinctive alveolar macrophage activation state induced by cigarette smoking. Am J Respir Crit Care Med. 2005;172:1383-1392.
24. Reutershan J, et al: Sequential recruitment of neutrophils into lung and bronchoalveolar lavage fluid in LPS-induced acute lung injury. Am J Physiol Lung Cell Mol Physiol. 2005;289:L807-L815.
25. Balbi B: COPD: Is chemotaxis the key? Chest. 2003;123:983-986.
26. Hoffmann E, et al: Multiple control of interleukin-8 gene expression. J Leukoc Biol. 2002;72:847-855.
27. Strieter RM, et al: Cytokines. 2. Cytokines and lung inflammation: Mechanisms of neutrophil recruitment to the lung. Thorax. 1993;48:765-769.
28. Keatings VM, et al: Differences in interleukin-8 and tumour necrosis factor-? in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am J Respir Crit Care Med. 1996;153:530-534.
29. Beeh KM, et al: Neutrophil chemotactic activity of sputum from patients with COPD: Role of interleukin 8 and leukotriene B4. Chest. 2003;123:1240-1247.
30. Richman-Eisenstat JB, et al: Interleukin-8: An important chemoattractant in sputum of patients with chronic inflammatory airway diseases. Am J Physiol. 1993;264(4 Pt 1):L413-L418.
31. Chang YH, et al: Lymphotoxin beta receptor induces interleukin 8 gene expression via NFkappaB and AP-1 activation. Exp Cell Res. 2002;278:166-174.
32. Barnes PJ, et al: Nuclear factor-kappaB: A pivotal transcription factor in chronic inflammatory diseases. N Engl J Med. 1997;336:1066-1071.
33. Hayden MS, et al: Signaling to NF-kappaB. Genes Dev. 2004; 18:2195-2224.
34. Caramori G, et al: Nuclear localisation of p65 in sputum macrophages but not in sputum neutrophils during COPD exacerbations. Thorax. 2003;58:348-351.
35. Karimi K, et al: Toll-like receptor-4 mediates cigarette smoke-induced cytokine production by human macrophages. Respir Res. 2006;7:66.
36. Mechta-Grigoriou F, et al: The mammalian Jun proteins: Redundancy and specificity. Oncogene. 2001;20:2378-2389.
37. Ng KW, et al: The binding of a Fos/Jun heterodimer can completely disrupt the structure of a nucleosome. EMBO J. 1997;16:2072-2085.
38. Wodrich W, et al: Overexpression of oncoproteins in non-small cell lung carcinomas of smokers. Carcinogenesis. 1993;14:1121-1124.
39. Hirama N, et al: Increased surfactant protein-D and foamy macrophages in smoking-induced mouse emphysema. Respirology. 2007;12:191-201.
40. Walters MJ, et al: Cigarette smoke activates human monocytes by an oxidant-AP-1 signaling pathway: Implications for steroid resistance. Mol Pharmacol. 2005;68:1343-1353.
41. Culpitt SV, et al: Impaired inhibition by dexamethasone of cytokine release by alveolar macrophages from patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2003;167:24-31.
42. Ohta T, et al: Cigarette smoking decreases interleukin-8 secretion by human alveolar macrophages. Respir Med. 1998;92:922-927.
43. Dubar V, et al: In vitro acute effects of tobacco smoke on tumour necrosis factor alpha and interleukin-6 production by alveolar macrophages. Exp Lung Res. 1993;19:345-359.
44. Zhang G, et al: Toll-like receptor-mediated NF-kappaB activation: A phylogenetically conserved paradigm in innate immunity. J Clin Invest. 2001;107:13-19.
45. Maes T, et al: Murine TLR-4 is implicated in cigarette smoke-induced pulmonary inflammation. Int Arch Allergy Immunol. 2006;141:354-368.
46. DongW, et al: The IRAK-1-BCL10-MALT1-TRAF6-TAK1 cascademediates signaling to NF-kappaB from Toll-like receptor 4. J Biol Chem. 2006;281:26029-26040.
47. Shim JH, et al: TAK1, but not TAB1 or TAB2, plays an essential role in multiple signaling pathways in vivo. Genes Dev. 2005;19:2668-2681.
48. Irie T, et al: TAK1 mediates an activation signal from toll-like receptor(s) to nuclear factor-kappaB in lipopolysaccharide-stimulated macrophages. FEBS Lett. 2000;467:160-164.
49. Horng T, et al: TIRAP: An adapter molecule in the Toll signaling pathway. Nat Immunol. 2001;2:835-841. (Pubitemid 34906448)
50. Toshchakov V, et al: TLR-4, but not TLR-2, mediates IFN-beta-induced STAT1alpha/betadependent gene expression in macrophages. Nat Immunol. 2002;3:392-398.
51. Yamamoto M, et al: TRAM is specifically involved in the Toll-like receptor 4-mediated MyD88- independent signaling pathway. Nat Immunol. 2003;4:1144-1150.
52. Yamamoto M, et al: Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway. Science. 2003;301:640-643. (Pubitemid 36927946)
53. Anto RJ, et al: Cigarette smoke condensate activates nuclear transcription factor-kappaB through phosphorylation and degradation of IkappaB(alpha): Correlation with induction of cyclooxygenase-2. Carcinogenesis. 2002;23:1511-1518.
54. Smith SJ, et al: Inhibitory effect of p38 mitogen-activated protein kinase inhibitors on cytokine release from human macrophages. Br J Pharmacol. 2006;149:393-404.
55. Yang SR, et al: Cigarette smoke induces proinflammatory cytokine release by activation of NFkappaB and posttranslational modifications of histone deacetylase in macrophages. Am J Physiol Lung Cell Mol Physiol. 2006;291:L46-L57.
56. Ito K, et al: Cigarette smoking reduces histone deacetylase 2 expression, enhances cytokine expression, and inhibits glucocorticoid actions in alveolar macrophages. FASEB J. 2001;15:1110-1112.
57. Ito K., et al: Histone deacetylase 2-mediated deacetylation of the glucocorticoid receptor enables NF-kappaB suppression. J Exp Med. 2006;203:7-13.
58. Ito K, et al: Decreased histone deacetylase activity in chronic obstructive pulmonary disease.N Engl J Med. 2005;352:1967-1976. (Pubitemid 40638367)
59. Adcock IM, et al: Molecular mechanisms of corticosteroid actions. Monaldi Arch Chest Dis. 2000;55:256-266.
60. Ito K: Impact of post-translational modifications of proteins on the inflammatory process. Biochem Soc Trans. 2007;35:281-283.
61. Abdelmohsen K, et al: Phosphorylation of HuR by Chk2 regulates SIRT1 expression. Mol Cell. 2007;25:543-557.
62. Borra MT, et al: Substrate specificity and kinetic mechanism of the Sir2 family of NAD+- dependent histone/protein deacetylases. Biochemistry. 2004;43:9877-9887.
63. Yang SR, et al: Sirtuin regulates cigarette smoke-induced proinflammatory mediator release via RelA/p65 NF-kappaB in macrophages in vitro and in rat lungs in vivo: Implications for chronic inflammation and aging. Am J Physiol Lung Cell Mol Physiol. 2007;292:L567-L576.
64. Facchinetti F, et al: {alpha},{beta}-Unsaturated aldehydes in cigarette smoke release inflammatory mediators from human macrophages. Am J Respir Cell Mol Biol. 2007;37:617-623.
65. Birrell MA, et al: Impact of tobacco-smoke on key signaling pathways in the innate immune response in lung macrophages. J Cell Physiol. 2007;214:27-37.
66. Martin TR: Recognition of bacterial endotoxin in the lungs. Am J Respir Cell Mol Biol. 2000;23:128-132.
67. Hasday JD, et al: Bacterial endotoxin is an active component of cigarette smoke. Chest. 1999;115:829-835.
68. Brass DM, et al: Subchronic endotoxin inhalation causes persistent airway disease. Am J Physiol Lung Cell Mol Physiol. 2003;285:L755-L761.
69. George CL, et al: Endotoxin responsiveness and subchronic grain dust-induced airway disease. Am J Physiol Lung Cell Mol Physiol. 2001;280:L203-L213.
70. Mochida-Nishimura K, et al: Differential activation of MAP kinase signaling pathways and nuclear factor-kappaB in bronchoalveolar cells of smokers and nonsmokers. Mol Med. 2001;7:177-185.
71. Hollingsworth JW, et al: The role of Toll-like receptor 4 in environmental airway injury in mice. Am J Respir Crit Care Med. 2004;170:126-132.
72. Brass DM, et al: CD14 is an essential mediator of LPS induced airway disease. Am J Physiol Lung Cell Mol Physiol. 2007;293:L77-L83.
73. Hollingsworth JW, et al: The critical role of hematopoietic cells in lipopolysaccharide-induced airway inflammation. Am J Respir Crit Care Med. 2005;171:806-813.
74. Blackwell TS, et al: Cytokine-induced neutrophil chemoattractant mediates neutrophilic alveolitis in rats: Association with nuclear factor kappa B activation. Am J Respir Cell Mol Biol. 1994;11:464-472.
75. Carter AB, et al: Lipopolysaccharide-induced NF-kappaB activation and cytokine release in human alveolar macrophages is PKC-independent and TK- and PC-PLC-dependent. Am J Respir Cell Mol Biol. 1998;18:384-391.
76. Koch A, et al: Effect of smoking on MAP kinase-induced modulation of IL-8 in human alveolar macrophages. Eur Respir J. 2004;23:805-812.
77. Kim HJ, et al: p38 Mitogen-activated protein kinase up-regulates LPS-induced NF-kappaB activation in the development of lung injury and RAW264.7macrophages. Toxicology. 2006:225:36-47.
78. Papavlassopoulos M, et al: MaxiK blockade selectively inhibits the lipopolysaccharide-induced I kappa B-?/NF-kappa B signaling pathway in macrophages. J Immunol. 2006;177:4086-4093.
79. Kobayashi K, et al: IRAK-M is a negative regulator of Toll-like receptor signaling. Cell. 2002;110:191-202.
80. Zhang G, et al: Negative regulation of toll-like receptor-mediated signaling by Tollip. J Biol Chem. 2002;277:7059-7065.
81. O'Reilly SM, et al: Regulation of Toll-like receptor 4 signalling by A20 zinc finger protein. Biochem Biophys Res Commun. 2003;303:586-593.
82. Liang J, et al: CD44 is a negative regulator of acute pulmonary inflammation and lipopolysaccharide-TLR signaling in mouse macrophages. J Immunol. 2007;178:2469-2475.
83. Martin TR, et al: Leukotriene B4 production by the human alveolar macrophage: A potential mechanism for amplifying inflammation in the lung. Am Rev Respir Dis. 1984;129:106-111.
84. Crooks SW, et al: Leukotriene B4. Int J Biochem Cell Biol. 1998;30:173-178.
85. Crooks SW, et al: Bronchial inflammation in acute bacterial exacerbations of chronic bronchitis: The role of leukotriene B4. Eur Respir J. 2000;15:274-280.
86. Martin TR, et al: Relative contribution of leukotriene B4 to the neutrophil chemotactic activity produced by the resident human alveolar macrophage. J Clin Invest. 1987;80:1114-1124.
87. Profita M, et al: Muscarinic receptors, leukotriene B4 production and neutrophilic inflammation in COPD patients. Allergy. 2005:60:1361-1369.
88. Takahashi H, et al: Structure of the human neutrophil elastase gene. J Biol Chem. 1988;263:14739-14747.
89. Shapiro SD, et al: Neutrophil elastase contributes to cigarette smoke-induced emphysema in mice. Am J Pathol. 2003;163:2329-2335.
90. Hubbard RC, et al: Neutrophil accumulation in the lung in ? 1-antitrypsin deficiency. Spontaneous release of leukotriene B4 by alveolar macrophages. J Clin Invest. 1991;88:891-897.
91. Janoff A, et al:NHLBI workshop summary. Effects of tobacco smoke components on cellular and biochemical processes in the lung. Am Rev Respir Dis. 1987;136:1058-1064.
92. Hubbard RC, et al: Oxidants spontaneously released by alveolar macrophages of cigarette smokers can inactivate the active site of alpha 1-antitrypsin, rendering it ineffective as an inhibitor of neutrophil elastase. J Clin Invest. 1987;80:1289-1295.
93. Ogushi F, et al: Risk factors for emphysema. Cigarette smoking is associated with a reduction in the association rate constant of lung alpha 1-antitrypsin for neutrophil elastase. J Clin Invest. 1991;87:1060-1065.
94. Ganz T, et al: Defensins. Eur J Haematol. 1990;44:1-8.
95. Van Wetering S, et al: Effect of neutrophil serine proteinases and defensins on lung epithelial cells: Modulation of cytotoxicity and IL-8 production. J Leukoc Biol. 1997;62:217-226.
96. Spencer LT, et al: Role of human neutrophil peptides in lung inflammation associated with alpha1-antitrypsin deficiency. Am J Physiol Lung Cell Mol Physiol. 2004;286:L514-L520.
97. Coffey MJ, et al: Prolonged exposure to lipopolysaccharide inhibits macrophage 5-lipoxygenase metabolism via induction of nitric oxide synthesis. J Immunol. 2000;165:3592-3598.
98. Robbins RA, et al: Modulation of alveolar macrophage leukotriene B4 released by complement component C5. J Lab Clin Med. 1990;115:497-503.
99. Profita M, et al: 15(S)-HETE modulates LTB(4) production and neutrophil chemotaxis in chronic bronchitis. Am J Physiol Cell Physiol. 2000;279:C1249-C1258.
100. Petrich K, et al: The suppression of 5-lipoxygenation of arachidonic acid in human polymorphonuclear leucocytes by the 15-lipoxygenase product (15S)-hydroxy-(5Z,8Z,11Z,13E)- eicosatetraenoic acid:structure-activity relationship and mechanism of action. Biochem J. 1996;314:911-916.
101. Takata S, et al: Remodeling of neutrophil phospholipids with 15(S)-hydroxyeicosatetraenoic acid inhibits leukotriene B4-induced neutrophil migration across endothelium. J Clin Invest. 1994;93:499-508.
102. Laviolette M, et al: Decreased leukotriene B4 synthesis in smokers' alveolar macrophages in vitro. J Clin Invest. 1986;77:54-60.
103. Wieslander E, et al: Human alveolar macrophages from smokers have an impaired capacity to secrete LTB4 but not other chemotactic factors. Eur J Respir Dis. 1987;71:263-272.
104. Tardif J, et al: Inhibition of human alveolar macrophage production of leukotriene B4 by acute in vitro and in vivo exposure to tobacco smoke. Am J Respir Cell Mol Biol. 1990;2:155-161.
105. Balter MS, et al: Multiple defects in arachidonate metabolism in alveolar macrophages from young asymptomatic smokers. J Lab Clin Med. 1989;114:662-673.
106. Mobley A, et al: Selective inhibition of 5-lipoxygenase pathway in rat pulmonary alveolar macrophages by cigarette smoking. Biochim Biophys Acta. 1987;918:115-119.
107. Sugiyama Y, et al: Effects of smoking on the synthesis of leukotriene B4 by rat alveolar macrophages. Respiration. 1989;56:198-203.
108. Mao JT, et al: Modulation of pulmonary leukotriene B4 production by cyclooxygenase-2 inhibitors and lipopolysaccharide. Clin Cancer Res. 2004;10:6872-6878.
109. Droemann D, et al: Toll-like receptor 2 expression is decreased on alveolar macrophages in cigarette smokers and COPD patients. Respir Res. 2005;6:68.
110. Mukhopadhyay S, et al: Role of TNFalpha in pulmonary pathophysiology. Respir Res. 2006;7: 125.
111. Kriegler M, et al: A novel form of TNF/cachectin is a cell surface cytotoxic transmembrane protein: Ramifications for the complex physiology of TNF. Cell. 1988;53:45-53.
112. Lundblad LK.et al: Tumor necrosis factor-alpha overexpression in lung disease: A single cause behind a complex phenotype. Am J Respir Crit Care Med. 2005;171:1363-1370.
113. Wilson AG, et al: Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc Natl Acad Sci U S A. 1997;94:3195-3199.
114. Huang SL, et al: Tumor necrosis factor-alpha gene polymorphism in chronic bronchitis. Am J Respir Crit Care Med. 1997;156:1436-1439.
115. Sakao S, et al: Association of tumor necrosis factor alpha gene promoter polymorphism with the presence of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001;163:420-422.
116. Jiang L, et al: Association of gene polymorphisms of tumour necrosis factor-alpha and interleukin-13 with chronic obstructive pulmonary disease in Han nationality in Beijing. Chin Med J (Engl). 2005;118:541-547.
117. Chierakul N, et al: Tumor necrosis factor-alpha gene promoter polymorphism is not associated with smoking-related COPD in Thailand. Respirology. 2005;10:36-39.
118. Kucukaycan M, et al: Tumor necrosis factor-alpha +489G/A gene polymorphism is associated with chronic obstructive pulmonary disease. Respir Res. 2002;3:29.
119. McCrea KA, et al: Altered cytokine regulation in the lungs of cigarette smokers. Am J Respir Crit Care Med. 1994;150:696-703.
120. Dandrea T, et al: Differential inhibition of inflammatory cytokine release from cultured alveolar macrophages from smokers and non-smokers by NO2. Hum Exp Toxicol. 1997;16:577-588.
121. Morimoto Y, et al: Synergistic effects of mineral fibres and cigarette smoke on the production of tumour necrosis factor by alveolar macrophages of rats. Br J Ind Med. 1993;50:955-960.
122. Lim S, et al: Balance of matrix metalloprotease-9 and tissue inhibitor of metalloprotease-1 from alveolar macrophages in cigarette smokers. Regulation by interleukin-10. Am J Respir Crit Care Med. 2000;162(4 Pt 1):1355-1360.
123. Takabatake N, et al: Circulating levels of soluble Fas ligand and soluble Fas in patients with chronic obstructive pulmonary disease. Respir Med. 2000;94:1215-1220.
124. Yu M, et al: Short-term exposure to aged and diluted sidestream cigarette smoke enhances ozoneinduced lung injury in B6C3F1 mice. Toxicol Sci. 2002;65:99-106.
125. Demirjian L, et al: Acute effect of cigarette smoke on TNF-alpha release by macrophages mediated through the erk1/2 pathway. Biochim Biophys Acta. 2006;1762:592-597.
126. Churg A, et al: {alpha}-1-Antitrypsin suppresses TNF{alpha} and MMP-12 production by cigarette smoke-stimulated macrophages. Am J Respir Cell Mol Biol. 2007;37:144-151.
127. Cosio BG, et al: Theophylline restores histone deacetylase activity and steroid responses in COPD macrophages. J Exp Med. 2004;200:689-695.
128. Vayssier M, et al: Tobacco smoke induces coordinate activation of HSF and inhibition of NFkappaB in human monocytes: Effects on TNFalpha release. Biochem Biophys Res Commun. 1998;252:249-256.
129. Kafoury RM, et al: Diesel exhaust particles induce the over expression of tumor necrosis factoralpha (TNF-alpha) gene in alveolar macrophages and failed to induce apoptosis through activation of nuclear factor-kappaB (NF-kappaB). Int J Environ Res Public Health. 2005;2:107-113.
130. Määttä J, et al: Comparison of hardwood and softwood dust-induced expression of cytokines and chemokines in mouse macrophage RAW 264.7 cells. Toxicology. 2006;218:13-21.
131. Maatta J, et al: Characterization of oak and birch dust-induced expression of cytokines and chemokines in mouse macrophage RAW 264.7 cells. Toxicology. 2005;215:25-36.
132. Honda Y, et al: Decreased contents of surfactant proteins A and D in BAL fluids of healthy smokers. Chest. 1996;109:1006-1009.
133. Alcorn J.F., et al: Surfactant protein A inhibits alveolar macrophage cytokine production by CD14-independent pathway. Am Physiol Lung Cell Mol Physiol. 2004;286:L129-L136.
134. Han J, et al: Interactive effects of the tumor necrosis factor promoter and 3--untranslated regions. J Immunol. 1991;146:1843-1848.
135. Jeong JY, et al: Tosylphenylalanine chloromethyl ketone inhibits TNF-alpha mRNA synthesis in the presence of activated NF-kappa B in RAW 264.7 macrophages. Immunology. 1997;92:267-273.
136. Lo CJ, et al: Macrophage TNF mRNA expression is modulated by protease inhibitors. J Surg Res. 1997;69:408-412.
137. Geppert TD, et al: Lipopolysaccharide signals activation of tumor necrosis factor biosynthesis through the ras/raf-1/MEK/MAPK pathway. Mol Med. 1994;1:93-103.
138. Swantek JL, et al: Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK) is required for lipopolysaccharide stimulation of tumor necrosis factor alpha (TNF-alpha) translation: glucocorticoids inhibit TNF-alpha translation by blocking JNK/SAPK. Mol Cell Biol. 1997;17:6274-6282.
139. Berclaz PY, et al: GM-CSF regulates a PU.1-dependent transcriptional program determining the pulmonary response to LPS. Am J Respir Cell Mol Biol. 2007;36:114-121.
140. Laza-Stanca V, et al: Rhinovirus replication in human macrophages induces NF-kappaBdependent tumor necrosis factor alpha production. J Virol. 2006;80:8248-8258.
141. Castro P, et al: Inhibition of interleukin-1beta reduces mouse lung inflammation induced by exposure to cigarette smoke. Eur J Pharmacol. 2004;498:279-286.
142. Churg A, et al: Tumour necrosis factor-alpha drives 70% of cigarette smoke-induced emphysema in the mouse. Am J Respir Crit Care Med. 2004;170:492-498.
143. Churg A, et al: Tumor necrosis factor-alpha is central to acute cigarette smoke-induced inflammation and connective tissue breakdown. Am J Respir Crit Care Med. 2002;166:849-854.
144. D'hulst AL, et al: Role of tumour necrosis factor-alpha receptor p75 in cigarette smoke-induced pulmonary inflammation and emphysema. Eur Respir J. 2006;28:102-112.
145. Churg A, et al: Macrophage metalloelastase mediates acute cigarette smoke-induced inflammation via tumour necrosis factor-alpha release. Am J Respir Crit Care Med. 2003;167:1083-1089.
146. Ishii Y, et al: Rat alveolar macrophage cytokine production and regulation of neutrophil recruitment following acute ozone exposure. Toxicol Appl Pharmacol. 1997;147:214-223.
147. Rolfe MW, et al: Pulmonary fibroblast expression of interleukin-8: A model for alveolar macrophage-derived cytokine networking. Am J Respir Cell Mol Biol. 1991;5:493-501.
148. Standiford TJ, et al: Interleukin-8 gene expression by a pulmonary epithelial cell line. J Clin Invest. 1990;86:1945-1953.
149. Li Y, et al: TNF-alpha up-regulates matrix metalloproteinase-9 expression and activity in alveolar macrophages from patients with chronic obstructive pulmonary disease. J Huazhong Univ Sci Technolog Med Sci. 2006;26:647-650.
150. Chung K.F: Cytokines in chronic obstructive pulmonary disease. Eur Respir J. 2001;Suppl 34:50s-59s.
151. Garofalo R, et al: Respiratory syncytial virus infection of human respiratory epithelial cells upregulates class I MHC expression through the induction of IFN-beta and IL-1 alpha. J Immunol. 1996;157:2506-3113
152. Yang GH, et al: Effects of interleukin-1 beta on DNA synthesis in rat alveolar type II cells in primary culture. Respirology. 1999;4:139-145.
153. Lappalainen U, et al: Interleukin-1beta causes pulmonary inflammation, emphysema, and airway remodeling in the adult murine lung. Am J Respir Cell Mol Biol. 2005;32:311-318.
154. Lucey EC, et al: Severity of elastase-induced emphysema is decreased in tumor necrosis factoralpha and interleukin-1beta receptor-deficient mice. Lab Invest. 2002;82:79-85.
155. Russell RE, et al: Release and activity of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 by alveolar macrophages from patients with chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol. 2002;26:602-609.
156. Wesselius L.J., et al: Rapid lung cytokine accumulation and neutrophil recruitment after lipopolysaccharide inhalation by cigarette smokers and nonsmokers. J Lab Clin Med. 1997;129:106-114.
157. Nagai S, et al: Smoking and interleukin-1 activity released from human alveolar macrophages in healthy subjects. Chest. 1988;94:694-700.
158. Rupp J, et al: Imbalanced secretion of IL-1beta and IL-1RA in Chlamydia pneumoniae-infected mononuclear cells from COPD patients. Eur Respir J. 2003;22:274-279.
159. Joos L, et al: Association of IL-1beta and IL-1 receptor antagonist haplotypes with rate of decline in lung function in smokers. Thorax. 2001;56:863-866.
160. Brown GP, et al: Cigarette smoking decreases interleukin 1 release by human alveolar macrophages. Am J Physiol. 1989;256:C260-C264.
161. Castranova V, et al: Effect of exposure to diesel exhaust particles on the susceptibility of the lung to infection. Environ Health Perspect. 2001;109(Suppl 4):609-612.
162. Yang HM, et al: Effects of diesel exhaust particles (DEP), carbon black, and silica on macrophage responses to lipopolysaccharide: Evidence of DEP suppression of macrophage activity. J Toxicol Environ Health A. 1999;58:261-278.
163. O'Brien-Ladner AR, et al: Iron is a regulatory component of human IL-1beta production. Support for regional variability in the lung. Am J Respir Cell Mol Biol. 2000;23:112-119.
164. O'Brien-Ladner AR, et al: Differential regulation of human alveolar macrophage-derived interleukin-1beta and tumor necrosis factor-alpha by iron. J Lab Clin Med. 1998;132:497-506.
165. Li YQ, et al: N-Acetyl-L-cysteine and pyrrolidine dithiocarbamate inhibited nuclear factor-kappaB activation in alveolar macrophages by different mechanisms. Acta Pharmacol Sin. 2006;27:339-346.
166. Strieter RM, et al: Acute lung injury: The role of cytokines in the elicitation of neutrophils. J Investig Med. 1994;42:640-651.
167. Becker S, et al: Constitutive and stimulated MCP-1, GRO alpha, beta, and gamma expression in human airway epithelium and bronchoalveolar macrophages. Am J Physiol. 1994;266(3 Pt 1):L278-L286.
168. Traves SL, et al: Increased levels of the chemokines GROalpha and MCP-1 in sputum samples from patients with COPD. Thorax. 2002;57:590-595.
169. Ko FW, et al: Exhaled breath condensate levels of 8-isoprostane, growth related oncogene alpha and monocyte chemoattractant protein-1 in patients with chronic obstructive pulmonary disease. Respir Med. 2006;100:630-638.
170. Chen HW, et al: Titanium dioxide nanoparticles induce emphysema-like lung injury in mice. FASEB J. 2006;20:2393-2395.
171. Carr MW, et al: Monocyte chemoattractant protein 1 acts as a T-lymphocyte chemoattractant. Proc Natl Acad Sci U S A. 1994;91:3652-3656.
172. de Boer WI, et al: Monocyte chemoattractant protein 1, interleukin 8, and chronic airways inflammation in COPD. J Pathol. 2000;190:619-626.
173. Kirkham PA, et al: Cigarette smoke triggers macrophage adhesion and activation: Role of lipid peroxidation products and scavenger receptor. Free Radic Biol Med. 2003;35:697-710.
174. Hautamaki RD, et al: Requirement for macrophage elastase for cigarette smoke-induced emphysema in mice. Science. 1997;277:2002-2004.
175. Capelli A, et al: Increased MCP-1 and MIP-1beta in bronchoalveolar lavage fluid of chronic bronchitics. Eur Respir J. 1999;14:160-165.
176. Bracke KR, et al: Cigarette smoke-induced pulmonary inflammation and emphysema are attenuated in CCR6-deficient mice. J Immunol. 2006;177:4350-4359.
177. Aldonyte R, et al: Circulating monocytes from healthy individuals and COPD patients. Respir Res. 2003;4:11.